Goa Game Changer: Indian State’s Health Authority Approves & Distributes Ivermectin & Doxycycline to Treat COVID-19 as Prophylaxis

Goa Game Changer: Indian State’s Health Authority Approves & Distributes Ivermectin & Doxycycline to Treat COVID-19 as Prophylaxis

Goa’s Chief Minister Pramod Sawant alongside State Health Minister Vishwajit Rane launched the ‘Home Isolation Kit’ to combat COVID-19. Apparently, the Indian state was influenced by Australia’s Dr. Thomas Borody and his combination treatment involving ivermectin and doxycycline (and zinc) targeting SARS-CoV-2, the virus behind COVID. Dr. Tarek Alam at the Bangladesh Medical College has also demonstrated the efficacy of the treatment in a hospital-approved case series study and is now conducting a randomized controlled study in that country. Back to beautiful southwestern India in Goa, calling it a “game-changer,” the Health Minister of this small Indian state is targeting the complete eradication of the virus in a people-centric home-based program. 

COVID-19 in Goa

The State of Goa in India, on the southwest coast, formerly a Portuguese colony, is home to about 2 million residents. It is a stunning region, geographically separated from the Deccan highlands by the Western Ghats. According to the state website, there have been 37,934 total cases reported since the onset of COVID-19, with 499 deaths. According to the Union Health Ministry, there are 31,920 total cases reported, with 4,716 active cases and 484 deaths.

The ‘Home Isolation Kit’

Ivermectin is approved by state authorities as the Health Minister himself participated in Panaji’s recent announcement last Friday. As reported in Big News Network, the Chief Minister declared that the kit would provide treatment for COVID-19 and enable better monitoring of patients at home.

This helps stop the spread of the pathogen in this part of India as the kit supports the patient remaining at home. Sawant reported in a Tweet, “Launched Home Isolation Kits for COVID-19 patients who have opted for home isolation. The kit will provide treatment and allow better monitoring of patients at home comfort. This is another pro-people step in our COVID-19 management in the state.”

What’s in the Kit

Health Minister Vishwajit Rane told the press that the home isolation kit would help treat the virus at an early stage and reduce the mortality numbers in Goa. The Health Minister quoted, “The newly launched Home Isolation Kit is a game-changer. We are using Ivermectin and Doxycycline for prophylaxis, which has no proven side effects. It gives me great pleasure to inform you that the use of Ivermectin for the treatment of patients is also followed by the Australian Government.”  

The Health Minister continued, “We will ensure every nook and corner of the state is equipped with care treatment facilities to tackle COVID-19.”

Other publications such as Business World corroborated the event.


TrialSite reports that the Australian government, at least at the national level, does not recommend Ivermectin for COVID-19. In fact, they are silent on the subject, according to NPS Medicine Wise. See the national guidelines.

On the topic of Ivermectin, the Therapeutic Goods Administration (TGA—the Australian FDA) is investigating the promotion of an ivermectin-based regimen for COVID-19.

Key Contact

Vishwajit Rane, Health Minster, State of Goa

Pharma Lobby and Hard Stance on Ivermectin—Connection?

Interestingly, it would appear that in developing nations (Peru, Bolivia, Dominican Republic) or in rapidly developing nations such as India (8th largest economy), Bangladesh, and Brazil, there appears to be a more pragmatic openness to Ivermectin among at least regional or local government health authorities than in the West where the pharmaceutical lobby is indeed powerful. TrialSite cannot prove any correlation however—it is merely an observation to ponder discussion.  

But in the meantime, in the United States, the world’s biggest economy and most sophisticated health system (including the pharmaceutical sector), has become the epicenter of the pandemic with nearly 8 million cases and 219,254 deaths as of this writing. 

Promising monoclonal antibodies are nearing emergency use authorization (EUA) from Regeneron and Eli Lilly, two great American companies. TrialSite picks up chatter from multiple data points, including trial site locations, not to mention POTUS himself, that these investigational products may work. However, this cannot be proven until one of the investigational products is authorized. 

Of course, the vaccines in development may help the fight as well. 

But America may need to be pragmatic as well—that great nation needs a multiplicity of approaches to take on this deadly pathogen.